Hindson Benjamin J.'s Form 4 filing
10x Genomics, Inc. (TXG) · filed Nov 3, 2021
- Accession no.
- 0001567619-21-019297
- Filed
- Nov 3, 2021
- Trade date
- Nov 1, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 7 non-derivative transactions and 2 derivative transactions. Open-market sales total $6.82M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Hindson Benjamin J.CIK 0001786391 | Director, Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 1, 2021 | Class A Common Stock | MOption exerciseAcquired | +10,232 | $5.04 | +$51,569.28 | 57,349 | Direct | |
| Nov 1, 2021 | Class A Common Stock | MOption exerciseAcquired | +31,434 | $11.48 | +$360,862.32 | 88,783 | Direct | |
| Nov 1, 2021 | Class A Common Stock | SSaleDisposed | −1,100 | $160.50F2 | −$176,550 | 87,683 | Direct | |
| Nov 1, 2021 | Class A Common Stock | SSaleDisposed | −1,500 | $162.06F3 | −$243,090 | 86,183 | Direct | |
| Nov 1, 2021 | Class A Common Stock | SSaleDisposed | −11,829 | $163.15F4 | −$1,929,901.35 | 74,354 | Direct | |
| Nov 1, 2021 | Class A Common Stock | SSaleDisposed | −24,125 | $163.87F5 | −$3,953,363.75 | 50,229 | Direct | |
| Nov 1, 2021 | Class A Common Stock | SSaleDisposed | −3,112 | $164.75F6 | −$512,702 | 47,117 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 1, 2021 | Class A Common Stock | MOption exerciseDisposed | −10,232 | $0.00 | $0 | 50,884 | Direct | |
| Nov 1, 2021 | Class A Common Stock | MOption exerciseDisposed | −31,434 | $0.00 | $0 | 68,566 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $160.00 to $160.95. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F3
This transaction was executed in multiple trades at prices ranging from $161.45 to $162.43. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F4
This transaction was executed in multiple trades at prices ranging from $162.48 to $163.475. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F5
This transaction was executed in multiple trades at prices ranging from $163.48 to $164.47. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F6
This transaction was executed in multiple trades at prices ranging from $164.50 to $165.29. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
Remarks
Chief Scientific Officer and President